Prosecution Insights
Last updated: April 19, 2026

Xencor, Inc.

12 pending office actions

Portfolio Summary

12
Total Pending OAs
0
Final Rejections
12
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19347570 HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS MCCOLLUM, ANDREA K 1674 Non-Final OA Oct 01, 2025
18744537 Fc VARIANTS WITH ALTERED BINDING TO FcRn DAHLE, CHUN WU 1641 Non-Final OA Jun 14, 2024
18587839 HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS AEDER, SEAN E 1642 Non-Final OA Feb 26, 2024
18456317 OPTIMIZED Fc VARIANTS DAHLE, CHUN WU 1641 Non-Final OA Aug 25, 2023
18033165 ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF SHUPE, ELIZABETH A 1643 Non-Final OA Apr 21, 2023
18300302 ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28 HAM, JIEUN 1643 Non-Final OA Apr 13, 2023
18296591 LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS METCALF, MATTHEW CURRAN 1647 Non-Final OA Apr 06, 2023
18065462 BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS MIDDLETON, DANAYA L 1674 Non-Final OA Dec 13, 2022
18053325 BISPECIFIC ANTIBODIES THAT BIND TO B7H3 AND NKG2D YOUTCHOM PENDIE, EMMANUEL LED 1647 Non-Final OA Nov 07, 2022
17817334 HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3 SKELDING, ZACHARY S 1644 Non-Final OA Aug 03, 2022
17692755 IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS PATTERSON, SARAH COOPER 1675 Non-Final OA Mar 11, 2022
17520590 HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII CHATTIN, AMY MARIE 1643 Non-Final OA Nov 05, 2021

Managing Xencor, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month